Abstract :

Adverse drug reactions (ADRs) remain a major global healthcare challenge, accounting for significant morbidity, mortality, treatment failure, and increased healthcare expenditure. Although clinical factors such as age, comorbidities, organ function, and polypharmacy contribute to ADR susceptibility, they inadequately explain the marked interindividual variability in drug response. Pharmacogenomics has emerged as a transformative approach to precision medicine by identifying inherited genetic variants that influence drug metabolism, transport, efficacy, and toxicity. This review critically examines the role of pharmacogenomic testing in predicting, preventing, and managing ADRs, with emphasis on clinically actionable pharmacogenes including CYP2D6, CYP2C19, TPMT, NUDT15, HLA-B15:02, HLA-B57:01, and HLA-B 58:01. Evidence from international pharmacogenomic guidelines demonstrates that genotype-guided prescribing significantly reduces severe hypersensitivity reactions, drug toxicity, and treatment failure while improving therapeutic efficacy and patient safety. The review further discusses current clinical applications, implementation challenges, ethical considerations, and emerging advances in genomic technologies, artificial intelligence, and clinical decision-support systems. The integration of pharmacogenomics into routine healthcare has the potential to optimize individualized drug therapy, minimize preventable ADRs, and accelerate the transition toward precision medicine, ultimately improving clinical outcomes and healthcare quality.

---

Keywords :

Pharmacogenomics; Adverse Drug Reactions; Precision Medicine; Pharmacogenetic Testing; Personalized Medicine.

---

References :

1. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA1998; 279:1200–5.CrossRefPubMedWeb of ScienceGoogle Scholar
2. Kvasz M, Allen IE, Gordon MJ, Ro EY, Estok R, Olkin I, et al . Adverse drug reactions in hospitalized patients: a critique of meta-analysis. MedGenMed2000; 2:E3.PubMedGoogle Scholar
3. YinY.ShuY.ZhuJ.LiF.LiJ. (2022). A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib. Sci. Rep.12, 19555. 10.1038/s41598-022-23834-1Pubmed Abstract CrossRef  Google Scholar
4. ChenJ.HuangL.ZengL.JiangZ.XiongM.JiaZ.-J.et al(2024b). The reference range of lamotrigine in the treatment of epilepsy in children: a systematic review. Eur. J. Clin. Pharmacol.80, 1–10. 10.1007/s00228-023-03562-9 CrossRef Google Scholar
5. BD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858.Article Google Scholar
6. Chan SL, Ng HY, Sung C, Chan A, Winther MD, Brunham LR, et al. Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. Pharmacogenomics J. 2019;19:401–10. https://doi.org/10.1038/s41397-018-0053-1.Return to ref 7 in article Article CAS PubMed Google Scholar
7. MiDatabank Adverse Drug Reaction (ADR) reporting – 2016 update, SPS—Specialist Pharmacy Service – The first stop for professional medicines advice. 2017. Accessed 6 Sep 2017. https://www.sps.nhs.uk/articles/midatabank-adverse-drug-reaction-adr-reporting-2016-update/.
8. Bahar M, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 2017;18:701–39. Article CAS PubMed Google Schola
9. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;285:540–544. doi: 10.1001/jama.285.5.540. [DOI] [PubMed] [Google Scholar]
10. Food and Drug Administration. Revised label for Purinethol. 2004. Available: http://www.fda.gov/medwatch/SAFETY/2004/jul_PI/Purinethol_PI.pdf. Accessed 28 December 2006.
11. Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov 2011;10:495–506[DOI] [PubMed] [Google Scholar]
12. Senn S Individual response to treatment: is it a valid assumption. BMJ 2004;329:966–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug Response. Mayo Clin Proc.2017;92(11):1711–1722. doi:10.1016/j.mayocp.2017.09.001.
14. Wang L, Weinshilboum RM. Pharmacogenomics in Practice. Clin Pharmacol Ther. 2019;106(5):936–938. doi:10.1002/cpt.1600.
15. Lu D.-Y., Lu T.-R., Xu B., Ding J. (2015). Pharmacogenetics of cancer therapy: breakthroughs from beyond?. Future Sci. OA 1 (4), FSO80. 10.4155/fso.15.80 [DOI] [PMC free article] [PubMed] [Google Scholar][Ref list]
16. Edwards I. R., Aronson J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. Lancet 356 (9237), 1255–1259. 10.1016/s0140-6736(00)02799-9 [DOI] [PubMed] [Google Scholar][Ref list]
17. Uetrecht J., Naisbitt D. J. (2013). Idiosyncratic adverse drug reactions: current concepts. Pharmacol. Rev. 65 (2), 779–808. 10.1124/pr.113.007450 [DOI] [PMC free article] [PubMed] [Google Scholar][Ref list]
18. Karnes JH, et al. Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology. 2019;59:463–486. DOI: 10.1146/annurev-pharmtox-010818-021818.
19. Jason H. Karnes, Matthew A. Miller, Katie D. White, Katherine C. Konvinse, Rebecca K. Pavlos, et al. 2019. Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology 59:463-486. https://doi.org/10.1146/annurev-pharmtox-010818-021818
20. Karnes JH, Miller MA, White KD, Konvinse KC, Pavlos RK, Redwood AJ, Peter JG, Lehloenya R, Mallal SA, Phillips EJ. Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:463-486. doi: 10.1146/annurev-pharmtox-010818-021818. Epub 2018 Aug 22. PMID: 30134124.
21. Karnes JH, Miller MA, White KD, Konvinse KC, Pavlos RK, Redwood AJ, Peter JG, Lehloenya R, Mallal SA, Phillips EJ. Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:463-486. doi: 10.1146/annurev-pharmtox-010818-021818. Epub 2018 Aug 22. PMID: 30134124; PMCID:PMC6409210.
22. Wang C-W, Preclaro IAC, Lin W-H and Chung W-H (2022) An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. Front. Pharmacol. 13:886377. doi: 10.3389/fphar.2022.886377
23. Chang CJ, Chen CB, Hung SI, Ji C, Chung WH. Pharmacogenetic    Testing for Prevention of Severe Cutaneous Adverse Drug Reactions. Front Pharmacol. 2020 Jul 2;11:969. doi: 10.3389/fphar.2020.00969. PMID: 32714190; PMCID: PMC7346738.
24. Kaloyan C, Koomdee N, Satapornpong P, Tempark T, Biswas M, Sukasem C. A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine. Pharmaceuticals (Basel). 2021 Oct 25;14(11):1077. doi: 10.3390/ph14111077. PMID: 34832859; PMCID: PMC8622011.
25. Sukasem C, et al. A comprehensive review of HLA and severe cutaneous adverse drug reactions. Front Pharmacol. 2021;12:718903. doi:10.3389/fphar.2021.718903.
26. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817.
27. Whirl-Carrillo M, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–572. doi:10.1002/cpt.2350.
28. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism. Pharmacol Ther. 2013;138(1):103–141. doi:10.1016/j.pharmthera.2012.12.007.
29. Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;112(3):569–576. doi:10.1002/cpt.2557.
30. Caudle KE, et al. Standardizing pharmacogenomic terminology. Clin Pharmacol Ther. 2021;110(3):563–572. doi:10.1002/cpt.2207.
31. Wilke RA, et al. The emerging role of transporter pharmacogenomics in precision medicine. Clin Pharmacol Ther. 2018;103(4):611–620.
32. Johnson JA, Caudle KE, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for warfarin therapy. Clin Pharmacol Ther. 2017;102(3):397–404.
33. Roden DM, et al. Pharmacogenomics of arrhythmias: ion channel variants and drug-induced long QT syndrome. Nat Rev Cardiol. 2019;16:421–436.
34. Rosenberg H, et al. Malignant hyperthermia susceptibility. Orphanet J Rare Dis. 2015;10:93.
35. Litman RS, et al. Malignant hyperthermia: update on susceptibility genes and pharmacogenetics. Anesthesiology. 2018;128(1):159–167.
36. Jaruthamsophon K, et al. Human leukocyte antigen alleles and immune-mediated adverse drug reactions. Annu Rev Pharmacol Toxicol. 2022;62:509–529. doi:10.1146/annurev-pharmtox-052120-014115.
37. Sukasem C, et al. A comprehensive review of HLA and severe cutaneous adverse drug reactions. Front Pharmacol. 2021;12:718903. doi:10.3389/fphar.2021.718903.
38. Karnes JH, et al. Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions. Annu Rev Pharmacol Toxicol. 2019;59:463–486. doi:10.1146/annurev-pharmtox-010818-021818.
39. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526:343–350. doi:10.1038/nature15817.
40. Caudle KE, et al. Standardizing pharmacogenomic terminology. Clin Pharmacol Ther. 2021;110:563–572. doi:10.1002/cpt.2207.
41. Whirl-Carrillo M, et al. An evidence-based framework for evaluating pharmacogenomics knowledge. Clin Pharmacol Ther. 2021;110:563–572. doi:10.1002/cpt.2350.
42. Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C9, VKORC1, and CYP4F2 genotypes and warfarin dosing. Clin Pharmacol Ther. 2017;102:397–404. doi:10.1002/cpt.668.
43. Pereira NL, et al. CPIC guideline for CYP2C19 genotype and clopidogrel therapy. Clin Pharmacol Ther. 2022;112:959–967. doi:10.1002/cpt.2526.
44. Ramsey LB, et al. CPIC guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;112:569–576. doi:10.1002/cpt.2557.
45. Phillips EJ, et al. Clinical pharmacogenetics implementation consortium guideline for HLA genotype and carbamazepine/phenytoin prescribing. Clin Pharmacol Ther. 2018;103:574–581. doi:10.1002/cpt.1037.
46. Sukasem C, et al. A comprehensive review of HLA and severe cutaneous adverse drug reactions. Front Pharmacol. 2021;12:718903. doi:10.3389/fphar.2021.718903.
47. Caudle KE, et al. HLA-B and CYP2C9 genotype-guided phenytoin therapy. Clin Pharmacol Ther. 2014;96:542–548.
48. Hicks JK, et al. CPIC guideline for CYP2D6 and CYP2C19 genotypes and antidepressant dosing. Clin Pharmacol Ther. 2023;114:51–68. doi:10.1002/cpt.2903
49. Swen JJ, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347–356. doi:10.1016/S0140-6736(22)01841-4.
50. Swen JJ, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347–356. doi:10.1016/S0140-6736(22)01841-4.
51. Swen JJ, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401:347–356. doi:10.1016/S0140-6736(22)01841-4.
52. Donnelly RS, Cavallari LH, McCune JS, Trofe-Clark J, Formea CM, Hoffecker G, Csere MM, Anderson KC, Bhat S, Mosley SA, Ma Q, Ferdock A, Hoffman JM, Hicks JK, Caudle KE. Decoding Pharmacogenomic Test Interpretation and Application to Patient Care. J Am Coll Clin Pharm. 2024 Jun;7(6):581-588. doi: 10.1002/jac5.1958. Epub 2024 May 8. PMID: 39582510; PMCID: PMC11583779.
53. Wake DT, Smith DM, Kazi S, Dunnenberger HM. Pharmacogenomic Clinical Decision Support: A Review, How-to Guide, and Future Vision. Clin Pharmacol Ther. 2022 Jul;112(1):44-57. doi: 10.1002/cpt.2387. Epub 2021 Aug 29. PMID: 34365648; PMCID: PMC9291515.
54. Peruzzi E,  Roncato R,  De Mattia E, et al.  Implementation of pre-emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? Br J Clin Pharmacol.  2025; 91(2): 270-282. doi:10.1111/bcp.15956
55. Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. Clin Pharmacol Ther. 2020 May;107(5):1240-1255. doi: 10.1002/cpt.1720. Epub 2019 Dec 17. PMID: 31715018; PMCID: PMC7232863.
56. Swen JJ, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet. 2023;401:347–356. DOI: 10.1016/S0140-6736(22)01841-4.
57. Tuteja S, et al. Economic Evaluations of Pharmacogenetic Testing: A Systematic Review and Quality Assessment. Pharmacoeconomics. 2022;40:613–640. DOI: 10.1007/s40273-022-01137-3.
58. Haga SB, Mills R. A Review of Ethical, Legal, and Social Implications of Pharmacogenetic Testing. Medical Principles and Practice. 2016;25(4):317–324. DOI: 10.1159/000446445.
59. Haga SB, Burke W. Pharmacogenetic Testing: Not as Simple as It Seems. Genetics in Medicine. 2008;10(6):391–395. DOI: 10.1097/GIM.0b013e31817702f1.